Switch theme
Sign up to access all valuation multiples
Amicus Therapeutics Inc is a patient-dedicated biotechnology company focused on discovering, developing and delivering novel high-quality medicines for people living with rare diseases. With extraordinary patient focus, the company is committed to advancing and expanding a pipeline of cutting-edge medicines for rare diseases. It has a portfolio of product opportunities, including oral precision medicine for people living with Fabry disease who have amenable genetic variants; a clinical-stage, treatment paradigm for Pompe disease, and a rare disease gene therapy portfolio. The company has one segment focused on the discovery, development, and commercialization of therapies to treat a range of devastating rare and orphan diseases.
2002
499
LTM Revenue $558M
LTM EBITDA $59.6M
$2.3B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Amicus Therapeutics has a last 12-month revenue of $558M and a last 12-month EBITDA of $59.6M.
In the most recent fiscal year, Amicus Therapeutics achieved revenue of $528M and an EBITDA of $29.4M.
Amicus Therapeutics expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Amicus Therapeutics valuation multiples based on analyst estimates| FY 2023 | FY 2024 | FY 2025 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | $399M | $528M | XXX | XXX | XXX |
| Gross Profit | $291M | $362M | XXX | XXX | XXX |
| Gross Margin | 73% | 69% | XXX | XXX | XXX |
| EBITDA | -$92.1M | $29.4M | XXX | XXX | XXX |
| EBITDA Margin | -23% | 6% | XXX | XXX | XXX |
| Net Profit | -$237M | -$152M | XXX | XXX | XXX |
| Net Margin | -59% | -29% | XXX | XXX | XXX |
| Net Debt | $243M | $141M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of April 15, 2025, Amicus Therapeutics's stock price is $7.
Amicus Therapeutics has current market cap of $2.1B, and EV of $2.3B.
See Amicus Therapeutics trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $2.3B | $2.1B | XXX | XXX | XXX | XXX | $-0.12 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of April 15, 2025, Amicus Therapeutics has market cap of $2.1B and EV of $2.3B.
Amicus Therapeutics's trades at 4.0x LTM EV/Revenue multiple, and 37.9x LTM EBITDA.
Analysts estimate Amicus Therapeutics's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for Amicus Therapeutics and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | $2.3B | XXX | XXX | XXX |
| EV/Revenue | 4.3x | XXX | XXX | XXX |
| EV/EBITDA | 76.8x | XXX | XXX | XXX |
| P/E | -36.8x | XXX | XXX | XXX |
| P/E/Growth | n/a | XXX | XXX | XXX |
| EV/FCF | -60.3x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpAmicus Therapeutics's NTM/LTM revenue growth is 20%
Amicus Therapeutics's revenue per employee for the last fiscal year averaged $1.1M, while opex per employee averaged $0.9M for the same period.
Over next 12 months, Amicus Therapeutics's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate Amicus Therapeutics's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for Amicus Therapeutics and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | 32% | XXX | XXX | XXX | XXX |
| EBITDA Margin | 6% | XXX | XXX | XXX | XXX |
| EBITDA Growth | -132% | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | 26% | XXX | XXX | XXX | XXX |
| Revenue per Employee | $1.1M | XXX | XXX | XXX | XXX |
| Opex per Employee | $0.9M | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | 21% | XXX | XXX | XXX | XXX |
| Opex to Revenue | 84% | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Amicus Therapeutics acquired XXX companies to date.
Last acquisition by Amicus Therapeutics was XXXXXXXX, XXXXX XXXXX XXXXXX . Amicus Therapeutics acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign Up| When was Amicus Therapeutics founded? | Amicus Therapeutics was founded in 2002. |
| Where is Amicus Therapeutics headquartered? | Amicus Therapeutics is headquartered in United States of America. |
| How many employees does Amicus Therapeutics have? | As of today, Amicus Therapeutics has 499 employees. |
| Who is the CEO of Amicus Therapeutics? | Amicus Therapeutics's CEO is Mr. Bradley L. Campbell. |
| Is Amicus Therapeutics publicy listed? | Yes, Amicus Therapeutics is a public company listed on NAS. |
| What is the stock symbol of Amicus Therapeutics? | Amicus Therapeutics trades under FOLD ticker. |
| When did Amicus Therapeutics go public? | Amicus Therapeutics went public in 2007. |
| Who are competitors of Amicus Therapeutics? | Similar companies to Amicus Therapeutics include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Amicus Therapeutics? | Amicus Therapeutics's current market cap is $2.1B |
| What is the current revenue of Amicus Therapeutics? | Amicus Therapeutics's last 12-month revenue is $558M. |
| What is the current EBITDA of Amicus Therapeutics? | Amicus Therapeutics's last 12-month EBITDA is $59.6M. |
| What is the current EV/Revenue multiple of Amicus Therapeutics? | Current revenue multiple of Amicus Therapeutics is 4.0x. |
| What is the current EV/EBITDA multiple of Amicus Therapeutics? | Current EBITDA multiple of Amicus Therapeutics is 37.9x. |
| What is the current revenue growth of Amicus Therapeutics? | Amicus Therapeutics revenue growth between 2023 and 2024 was 32%. |
| Is Amicus Therapeutics profitable? | Yes, Amicus Therapeutics is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
